Table 2.
Overview of study population, disaggregated by type of TB population.
| DS-TB 1 Population (n = 4515) |
DR-TB 2 Population (n = 473) |
||
|---|---|---|---|
| Projects n (%) | Bangladesh Ethiopia Haiti Kyrgyzstan Namibia Philippines_1 Philippines_2 South Africa Tanzania Uganda Ukraine |
684 (15.1) 38 (0.8) 41 (0.9) 22 (0.5) 373 (8.3) 1161 (25.7) 686 (15.2) 1351 (29.9) 159 (3.5) |
122 (25.8) 109 (23.0) 242 (51.2) |
| DAT 3 type n (%) | 99DOTS evriMED VOT 4 |
2468 (64.5) 1320 (34.5) 41 (1.1) |
295 (62.4) 178 (37.6) |
| Sex n (%) | Female Male Unknown |
1389 (36.3) 2439 (63.7) 1 (0.0) |
176 (37.2) 296 (62.6) 1 (0.2) |
| Age median (IQR) 5 | 35 (27;46) | 38 (30;49) | |
| Age categories n (%) | 15–34 y/o 6 35–50 y/o >50 y/o |
1905 (49.8) 1250 (32.7) 674 (17.6) |
183 (38.7) 182 (38.5) 108 (22.8) |
| Enrollment period n (%) | First half Second half |
1944 (50.8) 1885 (49.2) |
273 (57.7) 200 (42.3) |
| HCF 7 n | 58 | 35 | |
| Time points n (%) | Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 |
3829 (100) 3651 (95) 3497 (91) 3347 (87) 3189 (83) 2982 (78) |
473 (100) 464 (98) 440 (93) 412 (87) 382 (81) 342 (72) |
| Doses taken manually registered n (%) | 120,324 (21.6) | 13,780 (21.9) |
1 DS-TB = drug-sensitive tuberculosis; 2 DR-TB= drug-resistant TB; 3 DAT = digital adherence technology; 4 VOT = video-observed therapy; 5 IQR = interquartile range; 6 y/o = years old; 7 HCF = health care facility.